Airsculpt Technologies Stock Intrinsic Value – AIRSCULPT TECHNOLOGIES Reports Second Quarter Earnings Results for Period Ending June 30, 2023

August 15, 2023

🌥️Earnings Overview

AIRSCULPT TECHNOLOGIES ($NASDAQ:AIRS) revealed their second quarter earnings results for the period ending June 30, 2023 on August 11, 2023. Total revenue for Q2 of FY2023 was USD 55.7 million – a rise of 12.2% from the same quarter in the prior year – and net income for the quarter was USD 1.8 million, a jump from 0.6 million in the same quarter of the prior year.

Market Price

The stock opened at $7.8 and closed at $7.7, a decrease of 1.8% from its closing price of $7.9 the previous day. The decrease in stock price reflects investors’ reaction to the company’s financial performance during the quarter. Operating income was also above expectations, reaching $9.5 million for the quarter.

Overall, the company’s financial performance was strong during the quarter, and investors responded positively in the market. Despite the slight decrease in stock price, AIRSCULPT TECHNOLOGIES remains well-positioned for future growth. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Airsculpt Technologies. More…

    Total Revenues Net Income Net Margin
    181.11 -12.81 -6.9%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Airsculpt Technologies. More…

    Operations Investing Financing
    25.42 -12.76 -27.14
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Airsculpt Technologies. More…

    Total Assets Total Liabilities Book Value Per Share
    217.28 135.81 1.43
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Airsculpt Technologies are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    60.0% -0.1%
    FCF Margin ROE ROA
    7.0% -0.2% -0.1%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Airsculpt Technologies Stock Intrinsic Value

    At GoodWhale, we analyzed AIRSCULPT TECHNOLOGIES‘s financials to determine their fair value. Using our proprietary Valuation Line, we determined the fair value of AIRSCULPT TECHNOLOGIES share to be around $9.5. Currently, AIRSCULPT TECHNOLOGIES stock is trading at $7.7, making it a fair price but it is undervalued by 18.6%. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    Its competitors are Ceres Ventures Inc, Mitesco Inc, Quick-Med Technologies Inc.

    – Ceres Ventures Inc ($OTCPK:CEVE)

    Ceres Ventures Inc is a publicly traded company with a market capitalization of 684.01k as of 2022. The company has a strong return on equity of 140.84%. Ceres Ventures Inc is engaged in the business of providing venture capital and private equity financing to companies in the United States.

    – Mitesco Inc ($OTCPK:MITI)

    Mitesco Inc is a company that focuses on delivering value through innovation and technology. They have a strong focus on their customers and are always looking for ways to improve their products and services. Their market cap is 13.64M as of 2022 and their ROE is 240.89%. This means that they are doing very well in terms of their profitability and are delivering value to their shareholders. Mitesco is a company that you should definitely keep an eye on as they continue to grow and innovate.

    – Quick-Med Technologies Inc ($OTCPK:QMDT)

    Quick-Med Technologies Inc is a medical technology company that develops, manufactures and markets advanced antimicrobial products for the healthcare and consumer markets. The company’s products are based on its proprietary Quick-Med Platform Technology, which is designed to provide broad-spectrum, long-lasting antimicrobial activity with a low risk of developing resistance. Quick-Med’s products are available in a variety of formulations, including gels, liquids, sprays, wipes and powders. The company’s products are sold under the Naturasil, MediNatura, Quick-Med and Evolve brands.


    AIRSCULPT TECHNOLOGIES has reported strong financial results for its second quarter ended June 30, 2023. Total revenue was USD 55.7 million, a 12.2% increase year-over-year. Net income was USD 1.8 million, up substantially from 0.6 million in the same quarter of the prior year.

    These robust figures demonstrate the company’s ability to grow and generate profits, and indicate that AIRSCULPT TECHNOLOGIES is a viable investment opportunity. Investors should monitor the company’s future performance to determine whether these results are indicative of sustained growth.

    Recent Posts

    Leave a Comment